AR-A000002 is a
drug which is one of the first compounds developed to act as a
selectiveantagonist for the
serotonin receptor5-HT1B,[1] with approximately 10x selectivity for 5-HT1B over the closely related
5-HT1D receptor.[2] It has been shown to produce sustained increases in levels of serotonin in the brain, and has
anxiolytic effects in animal studies.[3][4]
References
^Hudzik TJ, Yanek M, Porrey T, Evenden J, Paronis C, Mastrangelo M, et al. (March 2003). "Behavioral pharmacology of AR-A000002, a novel, selective 5-hydroxytryptamine(1B) antagonist". The Journal of Pharmacology and Experimental Therapeutics. 304 (3): 1072–84.
doi:
10.1124/jpet.102.045468.
PMID12604684.
S2CID20463714.
^Ahlgren C, Eriksson A, Tellefors P, Ross SB, Stenfors C, Malmberg A (September 2004). "In vitro characterization of AR-A000002, a novel 5-hydroxytryptamine(1B) autoreceptor antagonist". European Journal of Pharmacology. 499 (1–2): 67–75.
doi:
10.1016/j.ejphar.2004.07.067.
PMID15363952.
^Stenfors C, Ahlgren C, Yu H, Wedén M, Larsson LG, Ross SB (March 2004). "Effects of long-term administration of the 5-hydroxytryptamine1B receptor antagonist AR-A000002 to guinea pigs". Psychopharmacology. 172 (3): 333–40.
doi:
10.1007/s00213-003-1667-8.
PMID14652708.
S2CID25130658.
^Stenfors C, Hallerbäck T, Larsson LG, Wallsten C, Ross SB (March 2004). "Pharmacology of a novel selective 5-hydroxytryptamine1B receptor antagonist, AR-A000002". Naunyn-Schmiedeberg's Archives of Pharmacology. 369 (3): 330–7.
doi:
10.1007/s00210-004-0866-0.
PMID14758468.
S2CID21075322.
AR-A000002 is a
drug which is one of the first compounds developed to act as a
selectiveantagonist for the
serotonin receptor5-HT1B,[1] with approximately 10x selectivity for 5-HT1B over the closely related
5-HT1D receptor.[2] It has been shown to produce sustained increases in levels of serotonin in the brain, and has
anxiolytic effects in animal studies.[3][4]
References
^Hudzik TJ, Yanek M, Porrey T, Evenden J, Paronis C, Mastrangelo M, et al. (March 2003). "Behavioral pharmacology of AR-A000002, a novel, selective 5-hydroxytryptamine(1B) antagonist". The Journal of Pharmacology and Experimental Therapeutics. 304 (3): 1072–84.
doi:
10.1124/jpet.102.045468.
PMID12604684.
S2CID20463714.
^Ahlgren C, Eriksson A, Tellefors P, Ross SB, Stenfors C, Malmberg A (September 2004). "In vitro characterization of AR-A000002, a novel 5-hydroxytryptamine(1B) autoreceptor antagonist". European Journal of Pharmacology. 499 (1–2): 67–75.
doi:
10.1016/j.ejphar.2004.07.067.
PMID15363952.
^Stenfors C, Ahlgren C, Yu H, Wedén M, Larsson LG, Ross SB (March 2004). "Effects of long-term administration of the 5-hydroxytryptamine1B receptor antagonist AR-A000002 to guinea pigs". Psychopharmacology. 172 (3): 333–40.
doi:
10.1007/s00213-003-1667-8.
PMID14652708.
S2CID25130658.
^Stenfors C, Hallerbäck T, Larsson LG, Wallsten C, Ross SB (March 2004). "Pharmacology of a novel selective 5-hydroxytryptamine1B receptor antagonist, AR-A000002". Naunyn-Schmiedeberg's Archives of Pharmacology. 369 (3): 330–7.
doi:
10.1007/s00210-004-0866-0.
PMID14758468.
S2CID21075322.